A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study
- 18 November 2015
- journal article
- research article
- Published by Springer Nature in Investigational New Drugs
- Vol. 34 (1) , 112-118
Abstract
Summary Introduction Heat shock protein 90 (Hsp90) has been studied as a therapeutic target in many cancers. In preclinical trials, the Hsp90 ATPase inhibitor ganetespib demonstrated potent inhibition of solid tumor growth, with superior potency than prior Hsp90 inhibitors. Given the promising preclinical outcome and favorable pharmacologic properties of ganetespib, we conducted a phase II trial of single-agent ganetespib in patients with metastatic, castrate-resistant prostate cancer (mCRPC). The primary objective of the study was to determine the 6-month progression-free survival (PFS) rate. Methods Patients with mCRPC who had been previously treated with docetaxel were enrolled after meeting eligibility criteria. All patients received ganetespib at 200 mg/m2 on days 1, 8, and 15 of every 28 days (one cycle). Subjects who tolerated therapy were continued on ganetespib until disease progression. Considering that Hsp90 acetylation may confer insensitivity to Hsp90 inhibitors and maspin inhibits protein deacetylation, maspin-associated molecular markers were evaluated. Results Eighteen patients were recruited into the trial; most were Caucasian, had performance status 1, had received prior docetaxel, and were heavily pretreated. Of the 17 patients who were treated, none attained 6-month PFS. Only 2 patients achieved PFS > 4 months. The median PFS was 1.9 months. As per the study design, the trial was terminated after the interim analysis. The most frequent types of Grade 3 toxicity were dehydration, diarrhea, and fatigue. Molecular markers provided little additional insight regarding drug activity. Conclusions Ganetespib demonstrated minimal clinical activity in men with mCRPC. The true 6-month PFS rate was, at most, 0.20. Possible reasons for this include selection of a heavily pretreated patient population and lack of agent potency in patients with mCRPC.Keywords
Funding Information
- National Institutes of Health (CA022453)
- National Institutes of Health (CA127735)
- National Institutes of Health (CA084176)
- Fund for Cancer Research
- Ruth Sager Memorial Fund
This publication has 30 references indexed in Scilit:
- Role of the HSP90-Associated Cochaperone p23 in Enhancing Activity of the Androgen Receptor and Significance for Prostate CancerMolecular Endocrinology, 2012
- Evidence for Efficacy of New Hsp90 Inhibitors Revealed by Ex Vivo Culture of Human Prostate TumorsClinical Cancer Research, 2012
- Maspin Reprograms the Gene Expression Profile of Prostate Carcinoma Cells for DifferentiationGenes & Cancer, 2011
- Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cellsBMC Cancer, 2011
- Multicenter Phase II Trial of the Heat Shock Protein 90 Inhibitor, Retaspimycin Hydrochloride (IPI-504), in Patients With Castration-resistant Prostate CancerUrology, 2011
- A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Hormone-Refractory Metastatic Prostate CancerClinical Cancer Research, 2008
- Minireview: The Intersection of Steroid Receptors with Molecular Chaperones: Observations and QuestionsMolecular Endocrinology, 2008
- Maspin augments proteasome inhibitor‐induced apoptosis in prostate cancer cellsJournal of Cellular Physiology, 2007
- Endogenous Inhibition of Histone Deacetylase 1 by Tumor-Suppressive MaspinCancer Research, 2006
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989